Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours (Q43708720)

26 November 2017

title

Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours (English)

1 reference

26 November 2017

0 references

1 reference

2

1 reference

26 November 2017

10

1 reference

26 November 2017

12

1 reference

26 November 2017

G Spitaleri

1

1 reference

26 November 2017

C Pierantoni

3

1 reference

26 November 2017

T De Pas

4

1 reference

26 November 2017

C Noberasco

5

1 reference

26 November 2017

C Libbra

6

1 reference

26 November 2017

R González-Iglesias

7

1 reference

26 November 2017

L Giovannoni

8

1 reference

26 November 2017

A Tasciotti

9

1 reference

26 November 2017

H D Menssen

11

1 reference

26 November 2017

language of work or name

1 reference

17 November 2012

1 reference

Journal of Cancer Research and Clinical Oncology

26 November 2017

published in

1 reference

26 November 2017

volume

139

1 reference

26 November 2017

issue

3

1 reference

26 November 2017

page(s)

447-455

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-012-1327-7

26 November 2017

exact match

0 references

cites work

Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Systemic versus local therapy with recombinant tumor necrosis factor-alpha (r-TNF-alpha) in patients with advanced tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Selective targeted delivery of TNFalpha to tumor blood vessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Early destruction of tumor vasculature in tumor necrosis factor-alpha-based isolated limb perfusion is responsible for tumor response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-012-1327-7

Phase I study of recombinant tumor necrosis factor in cancer patients.

21 January 2018

1 reference

12 December 2020

Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases

1 reference

12 December 2020

Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha

1 reference

12 December 2020

Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability

1 reference

12 December 2020

Efficiency of recombinant human TNF in human cancer therapy

1 reference

12 December 2020

Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites

1 reference

12 December 2020

Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice

1 reference

12 December 2020

Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience

1 reference

12 December 2020

Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer

1 reference

12 December 2020

Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies

1 reference

12 December 2020

A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days

1 reference

12 December 2020

10.1007/S00432-012-1327-7

Identifiers

DOI

1 reference

26 November 2017

1 reference